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Abstract 
Chronic lymphocytic leukemia (CLL) is the most common clonal B-cell disorder 
characterised by clonal diversity, a relapsing and remitting course, and in its 
aggressive forms remains largely incurable. Current frontline regimes include agents 
such as fludarabine, which act primarily via the DNA damage response pathway. 
Key to this is the transcription factor p53. Mutations in the TP53 gene, altering p53 
functionality, are associated with genetic instability, and are present in aggressive 
CLL. Furthermore, the emergence of clonal TP53 mutations in relapsed CLL, 
refractory to DNA damaging therapy, suggests that accurate detection of sub-clonal 
TP53 mutations prior to and during treatment may be indicative of early relapse. In 
this study we describe a novel deep sequencing workflow using multiple 
polymerases to generate sequencing libraries (MuPol-Seq), facilitating accurate 
detection of TP53 mutations at a frequency as low as 0.3%, in presentation CLL 
cases tested. As these mutations were mostly clustered within the regions of TP53 
encoding DNA binding domains, essential for DNA contact and structural 
architecture, they are likely to be of prognostic relevance in disease progression. The 
workflow described here has the potential to be implemented routinely to identify rare 
mutations across a range of diseases. 
 
Introduction 
Cancer cells evolve over time into genetically diverse populations carrying clonal and 
sub-clonal somatically acquired mutations1,2-4. The emergence of a dominant, 
somatically mutated clone occurs when the mutation offers a survival or proliferative 
advantage over ‘competitor’ cells under the conditions in their microenvironment5, 6. 
Exploring the cellular heterogeneity of cancers may therefore identify sub-clonal 
mutations that drive clonal expansion under different conditions.  
Chronic lymphocytic leukemia (CLL) is a heterogeneous disorder, characterised by 
clonally expanded CD5 positive B-cells carrying a range of genetic abnormalities 
some of which segregate with disease severity3, 7, 8. As with many other forms of 
cancer, an important abnormality associated with poor overall outcome and 
refractoriness to DNA damaging therapy, is dysfunctional p539-16. 
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The transcription factor p53, encoded by the TP53 gene on chromosome 17p13, 
regulates the cell-cycle and apoptosis in response to cellular stress. Cellular stress in 
the form of therapy that irreversibly damages DNA (such as the purine analogue 
fludarabine routinely used to treat CLL), activates p53 to induce the expression of 
targets that stall cell-cycle progression17, 18. This stalling allows time for DNA repair, 
and if the repair process is unsuccessful, initiation of apoptosis17, 18. In keeping with 
the two-hit model of cancer19, the mutations of one TP53 allele are generally found in 
the context of monoallelic loss of the remaining wild-type allele at the 17p13 locus12.  
The reported frequency of TP53 mutations in CLL ranges from approximately 10% 
without treatment, rising to 50% in relapsed disease, refractory to DNA damaging 
therapy12, 15, 16. As recent next-generation sequencing studies suggest, the rise in 
frequency of clonal TP53 mutated populations following DNA damaging therapy 
most likely reflects an expansion of low abundance, TP53 mutated sub-clones often 
undetectable at presentation by conventional sequencing 2, 4, 16, 20.  The majority of 
TP53 mutations reported in CLL lie within the p53 DNA binding domain (exons 4 -
10)21, 22, which can alter its capacity to bind to target DNA sequences and induce 
transcription; such abnormalities would offer a distinct survival advantage when a 
cell is exposed to agents that irreversibly damage DNA8, 15, 16, 23, 24.  
Given the importance of p53 in conferring therapeutic response to DNA damaging 
agents, it is not surprising that detection of TP53 abnormalities at presentation has 
gained importance in informing treatment choices. Without an intact TP53 gene, 
standard chemotherapy options are supplanted by alternative therapies which do not 
rely on DNA damage to induce cytotoxicity such as the monoclonal antibody 
therapies ofatumumab (anti-CD20)25 and alemtuzumab (anti-CD52)26, 27, and newer 
small molecule inhibitors including  idelalisib (inhibitor of the delta isoform of 
phosphatidylinositol 3-kinase)28, and ibrutinib (inhibitor of Bruton’s Tyrosine 
Kinase)29, 30.  However, diagnostic recognition of TP53 abnormalities that can 
influence patient treatment is mostly restricted to fluorescence in situ hybridisation 
(FISH) identification of 17p deletion, and conventional Sanger sequencing of the 
TP53 mutational hotspot (exons 4 – 10), both of which lack the sensitivity to detect 
sub-clonally mutated TP53 populations. Alternative approaches such as high 
resolution melting still require a conventional sequencing step and also lack 
sensitivity. Although the microarray based p53 Amplichip (Roche), improves on 
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sensitivity with a detection limit as low as 2%31, it is limited in the type of mutation 
that it can detect.  
Deep sequencing platforms have the potential to solve the issue of sensitivity, and 
have identified sub-clones with a mutation frequency as low as 0.3% in CLL2-4, 15, 16. 
However, the depth of deep sequencing also leads to reporting of both systematic 
sequencing and amplification related errors, and distinguishing true variants from 
these events can be problematic32-34.  Most bioinformatics approaches predict true 
variants from errors without taking the individual error rate at specific base positions 
along a sequence into consideration, with verification of low frequency events often 
limited to repetition of sequencing over two independent runs 15, 16. 
In this study we describe MuPol-Seq, a novel deep sequencing workflow in which 
error-prone aspects of sample preparation and the sequencing process are 
controlled for using different forms of polymerases to prepare libraries, combined 
with a strict bioinformatics pipeline which considers the positional error rate at each 
base. By analysing deep sequencing from separate libraries generated from the 
same sample but using enzymatically different, high fidelity polymerases that incur 
error biases at different rates, our novel approach offers an improved confidence 
when calling true mutants (present in both libraries), from background errors 
(detectable in only one library). By testing both libraries on two separate sequencing 
runs, the possibility of detecting systematic errors imposed by the sequencing 
process itself is also improved. As a key aim in this study was to produce a deep 
sequencing strategy that could be introduced into routine diagnostics, a low cost, 
highly multiplexed workflow was implemented. We applied this approach to 
distinguish low abundance TP53 variations that may predict an individual response 
to DNA damaging therapy from background errors in presentation CLL cases, and 
evaluated the use of digital droplet PCR (ddPCR), a highly sensitive technique 
capable of detecting rare mutant-alleles, 35-38 to validate low abundance mutant base 
calls. In addition, in one case where a relapse sample was available we were able to 
show that TP53 mutations present at CLL diagnosis were also present at relapse by 
ddPCR following treatment with fludarabine. This is supportive of a contributory role 
of TP53 mutants in resistance to DNA damaging drugs, and highlights the need to 
investigate the clinical relevance of these sub-clones further using reliable, 
methodical approaches. 
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Results 
Variant identification using the MuPol-Seq pipeline 
Libraries were generated from each of the 35 CLL cases, using Long and Accurate 
Thermus aquaticus (LA Taq) and pfu-based Phusion, both high fidelity enzymatically 
different forms of polymerase (Figure 1). Of the 35 CLL cases sequenced using the 2 
forms of polymerase over 2 separate sequencing lanes as out-lined in the MuPol-
Seq strategy (Figure 1), sequencing data was acceptable for 33 cases with reads 
from only 2 cases discarded due to poor quality. By using two forms of polymerase 
over two sequencing lanes, it was possible to eliminate systematic errors (i.e. errors 
that only occur in only one library, or in one sequencing lane). The average read 
depth at any base position across the 8 kb region of TP53 was 11,000 reads. The 
overall distribution of sequences generated with each of the 40 tags used in the 
pooled preparations, was similar indicating a high degree of consistency in library 
generation (Supplementary Figure S2). 
The frequency of mismatches for all samples repeated on each lane and with both 
polymerases is shown in Figure 2. Note that the frequency of mismatched bases at 
each base position was taken into consideration when determining errors from true 
events. The errors are centred round a model mean of 0.003 and maximal error of 
0.01. Ratio’s greater than 0.01 are not expected to be a result of random errors 
within our sequencing protocol and should be either sub-clonal variants within the 
system or errors of PCR amplification. These effects can be observed more clearly 
when the repeats on each lane and with both forms of polymerase, are plotted 
together (Supplementary Figure S3). 
True variants were called where an observed frequency at a position was 
significantly increased from normal (p-value <0.05 adjusted for False Discovery Rate 
(FDR)), in each sequencing lane and using both forms of polymerase 
(Supplementary Table S1).  
A series of variant and wild-type allele dilutions for the g.7574775 C>T single 
nucleotide polymorphism (SNP) were also sequenced and analysed identically to the 
CLL patient genomic samples. Data generated for the SNP g.7574775 C>T allele 
shows that the frequency of variant reads are proportional to variant allele input 
(Supplementary Table S2). However, this does not necessarily equate to overall 
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sensitivity to detect variant alleles at frequencies defined at input, as this type of 
experiment would not take positional variation into account. 
 
Frequency and characteristics of sub-clonal TP53 mutations detectable at CLL 
presentation 
Using the described bioinformatics criteria and outlined strategy to accurately call 
true mutational events (Figure 1), 26% of cases (n=9) presented with a TP53 variant 
detectable by deep sequencing using the Illumina platforms. Of these, only 2 cases 
would have been identified as TP53 mutation carriers by Sanger sequencing which 
is generally accepted as having the sensitivity to detect mutated alleles at a 
frequency of 20%. All TP53 mutations detectable using our strategy could be found 
in the IARC TP53 database further supporting their validity (http://www-p53.iarc.fr). 
When assessing the number of mutations per case, it was evident that the majority 
of cases in this series presented with >1 mutation within the TP53 coding region (6 
out of 9; Table 1; Table 2), the average frequency being 2 mutated bases per case. 
In total 13 mutations, 12 representing minor clones, were identified spanning exons 4 
to 10 clustering in the DNA binding domain encompassing the major hotspot codons 
220, 237, 245, 248, 249, and 273 each mutated in at least 1 case (Table 2; Figure 
3). In particular, variants at codon 237, 245, 248, 249 and  273 all located within 
exons 7 and 8, occurred at higher frequency than variants at other codons (2%, 
7.2%, 19.3%, 36.7% and 59.5% compared to <2%, respectively). The majority of 
mutations within this hotspot were missense, with transitions more prevalent than 
transversions in the dataset overall. In particular, AG>TC transitions were over-
represented (Table 2), and this is consistent with similar studies analysing TP53 
mutations in presentation CLL using alternative sequencing approaches. In cases 
where the number of mutations detected in TP53 exceeded 2, the codon positions 
were mostly outside of the hotspot, and predominantly silent.  These same positions, 
in particular codon 80 and codon 90, were overrepresented in the patient cohort 
occurring in 3 or more CLL cases. 
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Frequency of TP53 mutations, including one relapse case, and their validation by 
ddPCR and TaqMan real-time allelic discrimination  
Overall, the frequency of mutations in this study ranged from 0.3% to 59.5%, and 
mutations with an occurrence of 0.6%, 7% and 19% were verified independently 
using TaqMan real-time PCR based on allelic discrimination (Supplementary Figure 
S4; Table 5), and ddPCR (Figure 4; Table 5). Wild-type genomic DNA from a case 
with no detectable TP53 mutations was employed as a control and patient samples 
carrying Y220C, R248W, or R273C, were analysed for mutation frequency. As 
shown in Figures 4 and Supplementary Figure 4, the mutant alleles could be 
separated from wild-type alleles using both methods, most clearly by ddPCR. 
In addition, mutations occurring at a frequency of approximately 20% or more 
(R248W, R249S, and G245V in cases 9, 2 and 26 respectively), were also verified 
by conventional Sanger sequencing (Figure 5). The results visualised by Sanger 
sequencing corresponded with the variant allele frequency observed in each of these 
cases by MuPol-Seq (Figure 5; Table 5).   
In one case (patient 9), a follow-up sample was available at relapse prior to further 
therapy. Mutations detectable in TP53 at presentation, were identified at a similar 
frequency at relapse by ddPCR in the hotspot region (variant allele frequency of 1% 
and 10.8% for Y220C and R248W respectively; Figure 4). This patient had 
previously received fludarabine-based therapy.  Interestingly, the frequency of TP53 
mutation Y220C increased from 0.43% to 1%, whereas the frequency of TP53 
mutation R248W decreased from 24% to 10.8% when analysed by ddPCR (Figure 
4.). Cytogenetic analysis by FISH, and further confirmation of mutational status was 
not possible at relapse as only a limited amount of archived DNA sample was 
available.  
 
The occurrence of sub-clonal mutations in cases featuring other poor prognostic 
markers 
TP53 mutation state was compared to known markers of poor prognosis: IGHV 
mutational status, 17p13 loss and 11q23 loss (Table 1). Of the 9 cases with mutated 
TP53, 7 were in the IGHV unmutated category. Of the 2 cases with a mutated IGHV 
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region (<98% homology with germ-line IGHV), 1 (patient 16) carried a number of 
very low frequency mutations outside of the major hotspot region, whilst the 
remaining case (patient 33), carried a missense mutation in the hotspot region at a 
frequency of 2%. 
Loss of one allele of TP53 through deletions of chromosome 17p often coincides 
with mutation of the remaining allele and is an indicator of overall poor survival as 
well as poor response to DNA damaging drugs. Indeed, 4 of the 9 cases with TP53 
mutations were also shown to be 17p- by FISH. In these cases, the mutations were 
focussed around the primary mutational hotspots (codons 220, 237, 245, 248, 249 
and 273), in exons 5 to 8. The patients with large mutated clones (2, 9 and 26), 
above the level of sensitivity of FISH, all showed 17p deletion (Figure 6). A mutated 
TP53 clone was detectable in only one case of 11q-, containing the ATM DNA repair 
gene, and this was outside of the major hotspot region (Table 1; Table 2). 
 
Discussion 
The capability of deep resequencing to distinguish low abundance, disease-relevant 
mutations without separation from a non-mutated background is advantageous not 
only in research, but also in a clinical setting as a diagnostic tool. In the context of 
leukemia, sampling of circulating tumour cells has the potential to reduce the need 
for invasive, often expensive procedures such as bone marrow or solid tumour 
biopsy and, as described in this study, can be achieved using a minimum quantity of 
genomic DNA.  Multiplexing using unique sample identifiers increases workload 
capacity and reduces cost. However, the sensitivity of deep sequencing also reports 
low frequency background errors generated by DNA polymerase during library 
preparation and the Illumina sequencing process itself32-34. Finding a way to 
distinguish low abundance mutants from systematic errors is therefore a key factor in 
the successful routine implementation of deep sequencing. 
In this study we addressed this issue using a strategy in which resequencing libraries 
were derived from amplicons generated using two enzymatically different DNA 
polymerases, LA Taq and Phusion, run on two independent sequencing runs, 
coupled with a robust bioinformatics pipeline. Although both enzymes incur an error 
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bias, predominantly towards transitions, Taq polymerase has a propensity to 
incorporate cytidine with template thymine, and at a higher frequency than that of 
Phusion34.  This bias allows some distinction of true variants from polymerase errors 
given that true variants are more likely to be present in sequences generated from 
both forms of polymerase, eliminating errors that are unique to a single library 
generated from either LA Taq polymerase or Phusion alone. Furthermore, in an 
attempt to identify or eliminate errors induced during the Illumina sequencing run 
itself, GC-rich regions being particularly susceptible, data from two independent 
sequencing runs was analysed following the removal of error-prone homopolymeric 
tracts (mostly intronic), with only identical variants appearing in both runs classed as 
true events34.  
Although other deep sequencing studies have attempted to validate low frequency 
TP53 events15, 16, our approach is distinguished by the incorporation of two forms of 
polymerase in the library preparation linked to sensitive validation using two 
approaches. Like Sanger sequencing the first approach, TaqMan based allelic 
discrimination, amplifies both wild-type and variant alleles in the same PCR reaction, 
but the ability to discriminate mutant alleles is enhanced by the presence of two 
distinctly labelled fluorescent probes, one labelled probe complementary to mutant-
alleles and the second differently labelled probe complementary to wild-type alleles. 
An advancement of the TaqMan based two-coloured probe approach, is ddPCR in 
which wild-type and mutant-alleles within an individual sample are partitioned into 
hundreds of droplets prior to PCR. This approach effectively increases the 
concentration of rare mutant-alleles within the limited number droplets in which they 
are contained, and in this study convincingly distinguished low abundance TP53 
mutant-alleles from more frequent wild-type alleles. Given that the number of cases 
of CLL carrying a TP53 mutation in this study was relatively low (26%), and the 
number of coinciding TP53 mutations within each of these cases only averaged at 2 
mutations per case, (a lower frequency than other deep sequencing studies 
examining TP53 clonality in CLL15) this suggests that systematic errors are being 
filtered out using the described strategy with genuine events reported. 
As somatic TP53 mutations are recognised as indicators of poor prognosis in a 
number of cancers39, we wanted to test whether our novel deep sequencing 
approach could identify low abundance mutations in early-stage disease. This may 
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provide information on disease progression, for example in response to p53- 
dependent therapy, using CLL as a model of disease. Our study concurred with 
other reports in that a proportion of CLL cases carry sub-clonal TP53 mutations at 
diagnosis undetectable by conventional sequencing techniques. The majority of 
these are missense transitions, correlating mostly with unmutated IGHV, a marker of 
a more aggressive disease15, 16. Sub-clonal mutations are important in cancer 
progression and may particularly contribute to the evolution of drug-resistant clones 
under the selective pressure of a therapy targeting the mutated pathway. In this 
study we were able to show (albeit in only one case), that the same TP53 mutations 
present at diagnosis emerge at relapse following treatment with DNA damaging 
fludarabine supporting TP53 mutants as contributors of drug-resistance. The ability 
to accurately detect low frequency events therefore offers a distinct clinical 
advantage over currently implemented diagnostic techniques. Specifically, only 3 of 
the 9 presentation CLL cases with mutated TP53 detected in this study carried 
mutations at a frequency, confidently detectable by Sanger sequencing. Furthermore 
TP53 deletion identifiable by FISH, the parameter most commonly used to measure 
TP53 abnormalities routinely, was only identifiable in 4 cases, two of which were the 
cases with coincident high mutation frequency of the remaining allele. Thus the 
majority of patients in this study would have been reported as TP53 wild-type. This 
supports the need for the implementation and further evaluation of sensitive 
sequencing approaches such as this to inform clinical decision making. This 
becomes increasingly important as alternative drugs, such as idelalisib40 and 
ibrutinib41, have been approved for previously untreated patients with CLL who have 
either deletion of 17p or a TP53 mutation. 
Interestingly, of the cases where 17p deletion correlated with variant TP53, at least 
one dominating TP53 clonal event was present at a significantly higher frequency 
than sub-clonal events in other cases within our series. Moreover, these high 
frequency events were specifically at residues 237, 245, 248, 249 and  273, 
encoding regions of the p53 DNA binding domain essential for DNA contact (in 
particular, codons 248 and 273), and structural architecture (codons 245 and 249)42, 
43. These sites correlate with known TP53 clustering patterns not only observed in 
CLL but also in other forms of cancer8, 43. Our report suggests a link between 17p 
deletion and high frequency TP53 mutational events at specific codons in CLL before 
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the added selective pressure of DNA-damaging treatment, albeit in a small number 
of cases. This is perhaps not surprising given that p53 binds to sequence specific 
response elements through its DNA binding domain controlling expression of cell-
cycle and apoptotic proteins. Missense mutations within this domain are therefore 
likely to disable these pathways, increasing overall cellular instability8, 42, 43. 
Furthermore, it is possible that this phenotype may confer resistance to DNA 
damaging therapy. Given that mutations in the p53 DNA binding domain are likely to 
offer a survival advantage under the selective pressure of fludarabine, it was 
suprising to find approximately half the sub-clonal frequency of R248W present in 
case 9 at relapse when compared to the presentation sample, when analysed by 
ddPCR. Interestingly, this coincided with a doubling in frequency of the Y220C DNA 
binding domain mutation also by ddPCR, in the same relapse and presentation 
samples. One possibility is that both abnormalities represent separate, competing 
sub-clones with the TP53 Y220C mutation conferring greater therapeutic resistance 
that the R248W TP53 mutation. Further, longitudinal analysis of this case, should 
additional material become available, could provide more detail of this unexpected 
finding. 
Unlike other studies, the majority of CLL cases in this study carrying TP53 mutations 
(5 out of 9), did not display deleted 17p. Given the bi-allelic nature of cancer-related 
genetic alterations, and the low frequency of mutational events in these 5 cases 
(<2%), this may simply reflect the lack of sensitivity of FISH to detect abnormal 17p 
when the occurrence of loss is in <5% of B-cells. Alternatively, it is possible that 
inactivating mechanisms undetectable by sequencing or FISH, such as copy neutral 
loss of heterozygosity are present12, 23, 44. A further possibility that is difficult to 
eliminate by sequencing, is that bi-allelic sub-clonal TP53 mutations in these 5 cases 
exist in a proportion of the cellular population.  However, given that the mutations 
predominantly observed in these cases were detectable outside of the mutational 
hotspot linked with TP53 dysfunction, it is possible that they are of no clinical 
relevance. This is supported by the low variant allele frequencies with the lack of a 
dominating sub-clone when compared to the mutational spectrum observed in 17p 
deletion carriers (Figure 6), with the majority of silent TP53 mutations detectable by 
deep sequencing being observed with the 17p intact group (Table 2). 
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Overall, this report describes an ultra-deep resequencing workflow that distinguishes 
low abundance TP53 mutations from background generated from known sources. 
This approach can accurately detect low abundance mutations present at CLL 
diagnosis some of which will alter functionality of p53 and may therefore drive clonal 
selection either alone or in response to DNA damaging therapy. Given the low costs 
of library preparation, the robustness of the bioinformatics pipeline, the requirement 
of only low amounts of genetic material from non-separated cells, and the ability to 
multiplex a number of samples, this system is applicable routinely. Future evaluation 
is required to determine whether the detected low frequency mutations can 
prospectively predict patient response to therapy. However given the known central 
role of p53 in chemotherapy responses this is a reasonable prediction.  
 
Materials and methods 
Patient samples 
Peripheral blood was collected prospectively from a cohort of 35 newly diagnosed 
CLL cases (Table 1), and 4 normal donors. The aim was to collect cases 
representative of the major, prognostically relevant groups in CLL (i.e. IGHV mutated 
and unmutated cases, and cases with or without loss of 17p, 13q, and 11q). 
Information on cytogenetics (generated by routine FISH), and IGHV mutational 
status45, was obtained from the Haematological Malignancy Diagnostic Services 
(HMDS), Leeds Teaching Hospitals. Likewise, flow cytometry analysis was available 
through HMDS, and the majority of the cohort presented with >70% CLL cells as 
assessed by CD5/CD19 positivity, distinguishable from other B-cell disorders using a 
B-cell panel of flow cytometry fluorescent markers (CD10, CD103, CD11c, CD185, 
CD196, CD19, CD20, CD200, CD22, CD23, CD25, CD27, CD305, CD31, CD38, 
CD39, CD43, CD45, CD49d, CD5, CD79b, CD81, CD95, IgD, IgG, IgM, Kappa, 
Lambda), alleviating the need for leukemic cell separation. An additional sample was 
available for case 9; a DNA extraction from a peripheral blood sample taken at 
relapse approximately 18 months after presentation sample. This patient had 
received fludarabine-based therapy. Ethical approval was gained prior to this study, 
and patient samples were collected in accordance with the Declaration of Helsinki 
(REC 04/Q1205/178).  
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Mononuclear cells were prepared from peripheral blood using the standard Ficoll-
Histopaque gradient centrifugation protocol (Lymphoprep, Axis-Shield), and DNA 
was extracted from mononuclear cell pellets using the Qiamp Blood minikit in 
accordance with manufacturer’s instructions (Qiagen). 
 
Preparation of wild-type/variant dilution series 
In order to show that our strategy can detect a variation proportional to the allele 
frequency, a case containing a homozygous variant single nucleotide polymorphism 
(SNP g.7574775 C>T), was diluted serially with a wild-type homozygous case for the 
same allele. Each dilution was then treated as an individual case, and was prepared, 
sequenced and analysed identically to patient samples.   
 
TP53 PCR, library preparation, and deep sequencing 
A novel strategy (Figure 1), was adopted by which each DNA sample was amplified 
with two different classes of DNA polymerase to generate either an 8 kb product, 
using Long and Accurate (LA) Taq polymerase (Takara) or three 3 kb products using 
pfu-based Phusion High Fidelity polymerase (Finnzymes) from genomic DNA 
representing the TP53 gene including coding exons 2 to 11, introns and the 
3’untranslated region (Figure 1; Supplementary Table S3). PCR products from 
amplification with LA Taq and Phusion were agarose gel purified using a Zymoclean 
gel extraction kit (Zymed). To generate sequencing libraries, the purified amplicon 
was sonicated (Bioruptor, Diagenode) to generate fragments of 200-300bp followed 
by column purification (Zymogen).  DNA was end-repaired for 30 minutes at room 
temperature using Klenow DNA polymerase, T4 DNA polymerase, and T4 DNA 
Polynucleotide Kinase (New England Biolabs), before addition of a dA-tail using 
Klenow 3’-5’ exonuclease (New England Biolabs) for 30 minutes at 37oC. Index-
tagged Y-shaped adapters (using a design based on Bentley et al, 200820; 
Supplementary Table 3), were then ligated using Quick ligase (New England 
Biolabs) for 30 minutes at room temperature followed by a 10 minute 70oC step to 
inactivate the enzyme. Products were column purified in-between each procedure, 
and size selection was then performed by excision of the 250-350bp tagged product 
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from a 2% GTG agarose gel (Lonza). The purified, tagged amplicon library was 
enriched and prepared for sequencing using Phusion Flash (Finnzymes), in a 14-
cycle reaction (Supplementary Table S1).  The size distribution of the final product 
was checked on an Agilent Bioanalyser (Agilent Technologies), and quantified using 
a picogreen based kit (Quant-iT, Invitrogen). Equal amounts of each uniquely tagged 
product were mixed to generate a multiplexed pool of up to 40 uniquely indexed 
samples which were run on two sequencing lanes to remove between run variations 
(Figure 1), and sequenced using either the GAIIx or the Hi-seq platforms (Illumina). 
 
Bioinformatics analysis 
Following sequencing, data was collected for analysis, and sorted into individual 
paired end fastq files for each sample and enzyme using bespoke Perl scripts. All 
sample fastq files were subject to quality control inspection using Fastqc 
(www.bioinformatics.babraham.ac.uk/projects/fastqc/),  trimmed when the base 
quality fell below a phred quality score of 30 and discarded when the read was less 
than 20 base pairs, using Prinseq lite software46, and adapterRemoval47. Reads 
passing quality control were aligned to the TP53  gene sequence in human genome 
version 19 (Genome Reference Consortium GRCh37), using the Burrow-Wheeler-
Alignment method48.  
The number of mismatched bases corresponding to the reference base (n) and the 
total number of base calls at a given position (N) were obtained using SAMtools: 
pileup49, and bespoke scripting in Perl. A mismatch ratio (R=n/N) was then 
calculated if the read depth exceeded 500 reads.  
In order to find genomic positions that possess a significant detectable increased 
number of mismatches, i.e. possible candidate somatic mutations, mismatch ratios 
were compared to a background distribution of mismatch ratios expected from 
normal samples, predominantly incorporating the reference base50. 
Sequences from the CLL cases under investigation were compared to sequences 
generated from normal samples by assuming the mismatches can be modelled as a 
Poisson distribution50. In brief, the distribution describes the probability of obtaining n 
mismatches in our sample of interest given a mean number of mismatches observed 
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in our normal population (Ȝ).  Ȝ is calculated as the mean mismatch ratio multiplied 
by read depth at that site in our sample of interest. 
Potential mutated genomic positions in a given sample were identified provided the 
mismatch ratio was greater than that of background distribution of samples, and 
passed the P-value cutoff (0.05) after multiple testing correction using the False 
Discovery Rate (FDR)51. However, significant candidates would only be called when 
this was repeated across all replicates (i.e. in both lanes of the sequencing run), and 
observed in sequence runs generated from both forms of polymerase (LA Taq and 
Phusion High Fidelity, Figure 1; Supplementary Table S1). The International Agency 
on Research for Cancer (IARC) TP53 database was used to annotate mutations 
based on their codon position (http://www-p53.iarc.fr). Additional information on the 
bioinformatics approach is given in the supplemental data. 
 
 
Validation by TaqMan Allelic Discrimination, digital droplet PCR, and Sanger 
Sequencing 
A proportion of variants detectable by our sequencing and bioinformatics approach 
were subjected to TaqMan based allelic discrimination (Applied Biosystems), ddPCR 
(QX200, Bio-Rad), and Sanger sequencing for validation. It was anticipated that 
ddPCR would be superior to TaqMan based allelic discrimination, as previous 
studies already show accurate detection of rare mutations at variant allele 
frequencies of 0.01% and below35-38. Sanger sequencing was adopted to confirm 
mutations present by MuPol-Seq at a frequency close to, or within the capabilities of 
Sanger sequencing detection and visualisation (20%).  
TaqMan Allelic Discrimination 
A separate TaqMan allelic discrimination mastermix was prepared for 3 of the mutant 
TP53 alleles (R248W, R273C, and Y220C) detected by Mu-Pol sequencing for which 
assays could be custom designed (Applied Biosystems).  Each mastermix, 
containing 1x TaqMan universal PCR mastermix (Applied Biosystems), 1x Assay-by-
Design mix (-a custom designed mix of mutant-specific FAM-labelled probe, wild-
type specific VIC-labelled probe, forward and reverse primers, Applied Biosystems; 
Supplementary Table S3), mixed with replicate serial dilutions (0 to 60ng) of genomic 
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DNA from TP53 variant cases or wild-type cases (detectable by deep sequencing), 
or ‘no template’ control (water) in a 96-well optical plate, as described in the 
manufacturer’s instructions (Applied Biosystems). Each plate was run on the Applied 
Biosystems 7700 thermocycler (thermocycle conditions, Supplementary Table S3), 
and real-time quantitative plots and end-point reads were generated using Applied 
Biosystems 7700 software in order to assess the presence/absence of mutated 
alleles. 
Digital Droplet PCR 
Digital droplet PCR is a technique based on the dilution of mutants away from wild-
type alleles by the partitioning of the genomic template into nanoliter droplets. In this 
study, droplets were formed from the same replicate serial dilutions of genomic DNA 
representing wild-type and variant TP53 alleles and 1 x Assay-by Design dye-
labelled probe/primer mixes as described for TaqMan Allelic discrimination, together 
with 2x ddPCR supermix for probes (Bio-Rad). In addition, ddPCR was also used to 
investigate the presence of TP53 mutations detectable at CLL diagnosis in case 9 
(Y220C and R248W), in the available relapse sample from the same case. Droplets 
were generated from each mix using droplet generation oil, droplet cartridges and 
gaskets, and a droplet generator (all products from Bio-Rad), following 
manufacturer’s guidelines. After transferring droplets to a PCR compatible plate 
(Eppendorf), amplifications were performed (thermocycling conditions shown in 
Supplementary Table S3), before loading each PCR plate into a QX200 droplet 
reader (Bio-Rad). The reader was operated using manufacturer’s guidelines and 
data was analysed using QX200 Quantalife Software (Bio-Rad). Thresholds were set 
manually based on clustering as described elsewhere38.  
Sanger Sequencing 
Genomic DNA from cases 26, 2 and 9 was amplified by standard PCR using the 
thermocycling conditions, and the 3.6Kb primer set (spanning the exon 7 region 
containing R254V, R249S, and R248W) shown in Supplementary Table S3. Each 
amplicon was run on a 1% agarose gel, and bands were excised and purified as 
described previously. Purified amplicons were sequenced using standard conditions 
by Source Biosciences (Nottingham), using an additional internal primer preceding 
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exon 7 (5’-CGACAGAGAGCGAGATTCCATC-3’). Sequences were aligned using 
Chromas Lite software version 2.1.1 (Technelysium). 
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Table 1. Characteristics of presentation CLL cases and corresponding TP53 
mutations as determined by deep sequencing 
Case Age  Sex Cytogenetics *IGHV  TP53   
  (years)   13q14- ࢾ17p13- 11q23
- 
status mutations 
1 86 male >95% No No Unmutated - 
2 86 female No 66% No Unmutated R249S, R273C 
3 45 male 61% No No Unmutated - 
4 53 female No No No Unmutated S90P 
5 69 male 59% No No Unmutated nd 
6 39 female No No No Unmutated - 
7 63 male 84% No No Unmutated S90P, R335R 
8 52 male No No No Unmutated - 
9 62 female No >95% No Unmutated Y220C, R248W (P +R) 
10 60 female 87% No No Unmutated T81T, S90P, T155P  
11 76 female No No 93% Unmutated S90P 
12 53 male 95% No No Unmutated - 
13 62 male 99% No No Mutated  - 
14 63 male 22% No No Mutated  nd 
15 53 male No No No Mutated  - 
16 56 male 91% No No Mutated  T81T, S90P, T155P, R333R, R335R 
17 67 male 95% No 95% Unmutated - 
18 63 male No 95% No Unmutated - 
19 63 male 88% No 96% Unmutated - 
20 46 male No No 98% Unmutated - 
21 68 male No 72% No Unmutated - 
22 54 male 94% No 93% Unmutated - 
23 46 male >95% >95% No Unmutated - 
24 68 male 91% No 90% Unmutated - 
25 49 male 90% No 92% Unmutated - 
26 65 female 25% 84% No Unmutated T81T, M160V, V197L, G245V 
27 67 nd 30% 72% No Unmutated - 
28 nd nd No No 95% Unmutated - 
29 64 male No No No Unmutated - 
30 nd nd No No No Unmutated - 
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31 57 male nd nd nd nd - 
32 79 female nd nd nd nd - 
33 66 male 76% 51% No mutated M237I 
34 53 male No No No Unmutated - 
35 56 female 96% No No mutated - 
 
* where ‘mutated’ is <98% homology with germ-line; ࢾ 17p13 deletion is monoallelic unless stated; - no mutations detectable by 
deep sequencing; nd, Data not available, as failed Mu-Pol Seq quality control.(P+R), mutations shown were present in case 9 
at presentation and relapse. 
 
 
 
Table 2. Description of cases, characteristic TP53 mutations, and variant allele 
frequency (VAF) of each TP53 mutation per case, as determined by multiple 
polymerase deep sequencing (P-value cut off <0.05, False Discovery Rate 
corrected) 
 
Cases 
(n=9)  
Allele description (Wt>Vt) Amino acid 
change 
Exon Effect of 
Variant  
VAF (%) 
2 transition G>A R273C 8 missense 7.2  
 transversion C>A R249S 7 missense 36.7  
4 transition A>G S90P 4 missense 1.4  
7 transversion A>C R335R 10 silent 0.5  
 transition A>G S90P 4 missense 1.1  
9 transition G>A R248W 7 missense 19.3  
 transition T>C Y220C 6 missense 0.6  
10 transversion T>G T155P 5 missense 1.1  
 transition A>G S90P 4 missense 1.0  
 transition T>C T81T 4 silent 1.4  
11 transition A>G S90P 4 missense 0.9  
16 transversion A>C R335R 10 silent 0.8  
 transition A>G R333R 10 silent 0.6  
 transversion T>G T155P 5 missense 1.4  
 transition A>G S90P 4 missense 1.1  
 transition T>C T81T 4 silent 1.8  
26 transversion C>A G245V 7 missense 59.5  
 transversion C>G V197L 6 missense 0.3  
 transition T>C M160V 5 missense 0.6  
 transition T>C T81T 4 silent 1.4  
33 transition C>T M237I 7 missense 2.0  
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Table 3. Summary of TP53 mutations detectable by deep sequencing, Sanger 
sequencing, TaqMan based allelic discrimination, and digital droplet PCR. 
Case Variant Mu-Pol Seq VAF
൪
ddPCR VAF (SD) Sanger End-point 
2 R273C 7.2      9.9(±0.83)   - Detected 
 R249S 36.7      -             Detected - 
9P R248W 19.3    24(±1.9)             Detected Detected 
 Y220C 0.6    0.48(±0.09)            - Detected 
9R R248W -   10.8 (±0.25)                        -             - 
 Y220C -   1 (±0.14)                       - - 
26 G245V 59.5 -              Detected - 
ࢾ digital droplet PCR, Standard Deviation (SD) of variant allele frequency’s (VAF), based on replicates. 9P, presentation sample 
for case 9, whereas 9R is the relapse sample for the same case.  
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Figure 1. Schematic representation of the technical strategy to identify minor 
TP53 variants from background errors using multiple polymerases to prepare 
libraries prior to deep sequencing 
 
Figure 2. Frequency distribution of mismatch ratios averaged over chronic 
lymphocytic leukemia cases across all loci and non-reference bases. 
 
Figure 3. Schematic representation of the p53 protein showing functional 
domains with corresponding amino acid positions. Symbols shown above 
representation show the positions and nature of the TP53 mutations detected 
by deep sequencing.  
 
Figure 4. Quantitative digital droplet PCR (A) and end point TaqMan based 
allelic discrimination PCR to detect TP53 variants Y220C (upper plots) and 
R248W (lower plots) in patient 9. (A) Variant-containing droplets (FAM- 
labelled, shown as blue dots) are quantified by comparison with wild-type 
droplets (VIC-labelled, shown as green dots) (B) TaqMan based PCR 
demonstrating clear discrimination of variant-containing wells (FAM-labelled 
probe, shown as red symbols) from wild type-containing wells (VIC-labelled 
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probe, shown as blue symbols) for patient 9 dilution series.  In both, vertical 
axis is FAM channel fluorescence and horizontal axis is VIC channel 
fluorescence. 
 
Figure 5. Sanger sequencing of TP53 mutations detectable by deep 
sequencing at a frequency of (A) 59.5% in case 26 (G245V, C>A), (B) 36.7% in 
case 2 (R249S, C>A), and (C) 19.3% in case 9 (R248W, G>A).  
  
Figure 6. Frequency and amino acid position of TP53 mutations detectable by 
deep sequencing in 17p deleted (lower plot), and 17p wild-type (upper plot) 
CLL patients. 
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TD1/2 – transactivation domains; PR – proline-rich regions; TD –Tetramerization domain; 
RD – regulatory domain; mut - mutation 
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